Back to results
US 11,447,483 B2Granted
Tripartite androgen receptor eliminators, methods and uses thereof
AssigneeSPG Therapeutics, Inc.
InventorZory Shaposhnik
Life of this patent
Estimating the term…
Abstract
The present specification discloses tripartite androgen receptor eliminators (AREs), pharmaceutical compositions and medicaments comprising such AREs, methods and uses for such AREs and compositions and medicaments, and methods and uses for AREs and compositions and medicaments for treating an androgen receptor signaling-mediated condition, disease or disorder.
Claims11
A compound having the structure of formula I,
- wherein ARA is an AR antagonist that is apalutamide, bicalutamide, canrenone, chlormadinone acetate, cimetidine, cyproterone acetate, drospirenone, enzalutamide, flutamide, ketoconazole, megestrol acetate, nilutamide, RU58841, spironolactone, topilutamide (fluridil),
A pharmaceutical composition comprising:
- 0.1% to 10% of a compound having the structure of
- wherein ARA is an AR antagonist that is apalutamide, bicalutamide, canrenone, chlormadinone acetate, cimetidine, cyproterone acetate, drospirenone, enzalutamide, flutamide, ketoconazole, megestrol acetate, nilutamide, RU58841, spironolactone, topilutamide (fluridil),
- 20% to 40% denatured alcohol,
- 40% to 60% isopropyl myristate, and
- 10% to 30% diethylene glycol monoethyl ether.
2 more elements
A pharmaceutical composition comprising:
- 0.5% to 5% of a compound having the structure of
- wherein ARA is an AR antagonist that is apalutamide, bicalutamide, canrenone, chlormadinone acetate, cimetidine, cyproterone acetate, drospirenone, enzalutamide, flutamide, ketoconazole, megestrol acetate, nilutamide, RU58841, spironolactone, topilutamide (fluridil),
- 25% to 35% denatured alcohol,
- 45% to 55% isopropyl myristate, and
- 15% to 25% diethylene glycol monoethyl ether.
2 more elements
Dependencies are inferred from the claim text.